explore -WSS

explore

author：knowledge 2025-09-03 09:27:54 - browse：84692

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Cytokinetics CEO stresses company can launch heart drug on its own

WSS

Arc Institute generative AI designs new CRISPR systems

Psychedelics group wrestles with new pharma identity

Jerome Adams on the need for new antivirals for Covid

The cancer drug shortage isn’t new — and neither are the solutions

Bird flu: Don't repeat Covid's 'health versus the economy' framing

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

focus

explore

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Affirmative action in medical school literally saved lives

DIEP, the 'gold standard' of breast reconstruction, is under threat

Affirmative action in medical school literally saved lives

In age of alternative facts, a scholarly course on calling out crap

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Sports medicine is finally prioritizing gender equality

In age of alternative facts, a scholarly course on calling out crap

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

entertainment

Cancer drug shortages should be causing more outrage

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Dobbs anniversary: the lost opportunity of abortion as health care

Second House panel advances two

Addiction experts warn against a second 'war on drugs'

Apple is now the first public company to be valued at $3 trillion

hotspot

focus

focus

focus